EHA news
H-Net, the 3-year European Network for Harmonization of Training in Hematology project led by Professor Eva Hellström-Lindberg, ended in September 2011, but its strongest components continue. The project is an assembly of 22 of the most important hematology organizations in Europe (and beyond) working to improve the mobility of students and professionals by raising their skills to an equally high standard across countries.
For the whole text, of this early release paper in Haematologica: http://www.haematologica.org/content/early/2012/10/29/haematol.2012.078964.abstract
The Leukemia Patient Advocates Foundation, the legal host of the CML Advocates Network, proudly announced the launch of phase 2 of its International CML Adherence Survey. The survey was launched in 12 countries on International CML Awareness Day (22 Sept 2012). As it is organized by the non-profit patient community, this research work urgently needs your support now: If you are a CML patient treated with TKI, please participate. If you are a doctor treating CML patients: Please encourage your patients to participate!
BRUSSELS, September 18 2012:
Today, Nessa Childers, MEP hosted the launch of the Manifesto of the European Alliance for Personalised Medicine in the European Parliament.
The Manifesto sets out both the opportunities and challenges of ‘a targeted approach to the prevention, diagnosis and treatment of disease based on an individual’s specific profile’ - what is known as personalised medicine.
Currently available treatments for disease have revolutionised health in Europe and beyond, but science has now brought healthcare to the brink of another major evolution.
By a combination of molecular medicine and computer technology, it is becoming possible for screening of patients, early treatment, or prevention to be calibrated precisely, to deliver with maximum effectiveness. With personalised medicine, healthcare services will ensure the right intervention to the right patient at the right time - improving patient outcomes, reducing the likelihood of adverse events, and cutting down unnecessary treatments.
AMSTERDAM – June 16, 2012 –The European Hematology Association (EHA), the American Society of Hematology (ASH), and the European Cancer Patient Coalition (ECPC) joined today in issuing a common call to action in an effort to mitigate shortages of hematologic drugs in Europe, the United States and around the world. The collective made the announcement today following the EHA-ASH Joint Symposium at the 17th EHA Congress in Amsterdam which was dedicated to the drug shortage crisis.
Laurent Degos will be the fifth recipient of the Jean Bernard Lifetime Achievement Award which was presented for the first time at the 13th Congress in Copenhagen. This award was established to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.
The EHA Board has selected Professor Jesús San Miguel for the José Carreras Lecture at the 17th Congress in Amsterdam. Jesús San Miguel is Professor of Medicine (Haematology), Head of the Hematology Department at the University Hospital of Salamanca, and Director of the Biomedical Research Institute of Salamanca, Spain. He is an internationally recognized leader in the field of hematology, and specifically in the area of multiple myeloma.
Amsterdam, June 15, 2012. “There is a large potential opportunity for saving lives by early identification of cardiac iron loading in Thalassemia patients”, declares Professor John-Paul Carpenter of the Royal Brompton CMR Unit in London at the 17th Congress of the European Hematology Association in Amsterdam.
Amsterdam, June 15, 2012. At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.
Amsterdam, June 15, 2012. Dr Micheal Hedenus of the Haematology Unit of the Sundsval Hospital in Sweden will present promising results on a study on a single iron dose for fatigue treatment in iron deficient women at the 17th Congress of the European Hematology Association in Amsterdam.
Amsterdam, June 15, 2012. “Hodgkin lymphoma has become one of the most curable malignancies in adults,” was stated by Dr Andreas Engert, Professor of Hematology at the University Hospital of Cologne in Germany. Results of the German Hodgkin Study Group (GHSG) HD 15 trial are presented at the 17th Congress of the European Hematology Association in Amsterdam.